FDA's Peptide Approval Could Spark New Telehealth Market
· news
The FDA’s Peptide Vote Could Create Telehealth’s Next Multibillion-Dollar Market
The biotech industry is abuzz with excitement over the potential approval of peptides, tiny protein fragments touted for their supposed health benefits. However, as the FDA’s compounding advisory committee prepares to weigh in on the matter, it’s worth examining the risks associated with this trend.
Peptides are essentially the latest darling of the wellness crowd, injected into the body and promising faster recovery, improved energy, and anti-aging benefits. Like Ozempic, a diabetes medication that became a multi-billion-dollar shadow industry two years ago, peptides have been quietly raking in cash for pharmacies and compounding centers willing to skirt regulations.
There’s a key difference between Ozempic and peptides: while the former had some clinical evidence backing its use, peptides are largely untested. Most popular peptides haven’t undergone large-scale human trials; instead, they’re sold as “research chemicals” outside normal drug-approval channels.
This lack of rigor is a recipe for disaster. Without long-term safety data, peptide enthusiasts are playing with fire. As more people stack multiple compounds at once – a common practice in the peptide community – risks multiply.
Telehealth companies like Hims & Hers are eyeing this trend with interest, sensing an opportunity to expand their offerings into another lucrative market. But what exactly is being sold here? Is it a genuine health solution or just a quick buck for companies and pharmacies willing to take on regulatory risks?
The FDA’s decision next week will be pivotal. If peptides are approved for compounding by pharmacies, expect a flood of copycat telehealth sites launching peptide “programs” almost overnight. However, this won’t necessarily mean that consumers will be better off – quite the opposite.
According to Jon Keidan, founder and managing partner of Torch Capital, the real battle isn’t about whether peptides are approved or not but how demand is channeled through regulated channels. If we’re honest with ourselves, it’s hard to see why this trend won’t play out in much the same way as GLP-1: big players will swoop in, muscling out smaller operators and leaving a trail of regulatory chaos.
The stakes are high, and regulators must take a closer look at what’s really being sold here. While peptides may seem like the latest wellness panacea, we owe it to ourselves – and our bodies – to approach this trend with skepticism.
Reader Views
- CSCorrespondent S. Tan · field correspondent
The FDA's peptide approval is more than just a vote on a new compound - it's a nod to the unregulated telehealth market that has been peddling peptides as "research chemicals". The lack of human trials and long-term safety data is alarming, but what's even more concerning is how easily these compounds can be stacked by enthusiasts with little understanding of potential interactions. Regulatory bodies need to scrutinize not just the peptides themselves, but also the telehealth platforms that will inevitably capitalize on this trend, potentially putting unsuspecting consumers at risk.
- CMColumnist M. Reid · opinion columnist
The FDA's peptide approval could indeed create a multibillion-dollar telehealth market, but let's not forget the dark side of this trend: the predatory practices of some compounding centers and pharmacies that have been selling peptides as "research chemicals" to unsuspecting customers. It's essential to scrutinize these companies' business models, which often prioritize profit over patient safety. With peptides being touted for anti-aging benefits, we're essentially creating a market for ageism, where people are encouraged to spend thousands on potentially untested and ineffective treatments rather than addressing the root causes of aging through evidence-based medicine.
- EKEditor K. Wells · editor
The FDA's peptide approval is being hailed as a potential telehealth goldmine, but let's not forget that peptides are essentially untested on a large scale. We're seeing a repeat of the Ozempic phenomenon, where unproven "research chemicals" are being pushed to desperate patients under the guise of wellness solutions. The real question is: what happens when these peptides interact with each other and our existing medications? Telehealth companies need to be transparent about the lack of long-term safety data and ensure that patients understand they're participating in a trial-by-commission, not receiving established medical care.